5-HTP Slow-Release Formulation for CNS Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for CNS disorders using serotonin-enhancing drugs, such as SSRIs, have limitations due to the short half-life of 5-HTP leading to fluctuating plasma levels, frequent dosing, gastrointestinal side effects, and risks of serotonin syndrome, particularly in non-responders and patients with mood fluctuations.

Innovation Solution

A slow-release formulation of 5-hydroxytryptophan combined with a serotonin-enhancing compound, administered in a therapeutically effective amount, to maintain steady serotonin levels and reduce side effects, enhancing the efficacy of treatments for CNS disorders like depression, anxiety, and bipolar disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If immediate-release formulation of 5-HTP is used, then rapid serotonin conversion is achieved, but plasma levels fluctuate significantly and multiple daily doses are required

Engineering Contradiction:

Improverate of serotonin conversionVSAvoidplasma level stability

Core Design Contradiction:

SpeedVSStability of the object's composition

Solution Approach 1:

The immediate-release 5-HTP formulation is segmented into multiple smaller doses administered throughout the day, which maintains more stable plasma levels while preserving the rapid serotonin conversion benefit of each individual dose

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Multiple periodic dosing throughout the day replaces single large doses, creating a rhythm of administration that maintains stable plasma concentrations while ensuring continuous serotonin synthesis

Inventive Principle:

Principle #19Periodic action

2Stability of the object's composition

If frequent dosing is used to maintain steady plasma levels, then plasma level stability improves, but dosing frequency increases and patient compliance decreases

Engineering Contradiction:

Improveplasma level stabilityVSAvoiddosing frequency

Core Design Contradiction:

Stability of the object's compositionVSEase of operation

Solution Approach 1:

Multiple dosing occasions are merged into a single daily administration of a sustained-release formulation, which maintains plasma level stability while reducing the burden on the patient to remember and take multiple separate doses

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If high doses of 5-HTP are used to maintain therapeutic effect, then treatment efficacy improves, but gastrointestinal side effects increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidgastrointestinal adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The formulation dynamically releases 5-HTP at controlled rates over extended periods, maintaining therapeutic plasma levels without creating sudden peaks that trigger gastrointestinal side effects

Inventive Principle:

Principle #15Dynamics

4Speed

If rapid peak plasma levels are achieved after dosing, then treatment response is fast, but side effects such as nausea and vomiting occur

Engineering Contradiction:

Improveonset of treatment responseVSAvoidacute side effects

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

Instead of a single rapid peak, the formulation provides periodic, controlled releases of 5-HTP throughout the dosing interval, maintaining therapeutic levels without creating acute peaks that cause nausea and vomiting

Inventive Principle:

Principle #19Periodic action

5Reliability

If 5-HTP is used in combination with serotonin transporter inhibitors, then treatment efficacy for non-responders improves, but risk of serotonin syndrome increases

Engineering Contradiction:

Improvetreatment efficacy in non-respondersVSAvoidserotonin syndrome risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The sustained-release formulation provides dynamic, controlled release of 5-HTP over extended periods, maintaining therapeutic levels without creating acute spikes that would excessively stimulate serotonin receptors and trigger serotonin syndrome when combined with SSRIs

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The slow-release formulation of 5-HTP provides sustained serotonin levels, reducing the frequency of dosing, minimizing side effects, and potentially improving treatment outcomes for CNS disorders by enhancing the effectiveness of serotonin-enhancing compounds.

Implementation Method 1

a slow-release formulation of 5-hydroxytryptophan (5-HTP) or a pharmaceutically acceptable salt thereof

Methodology Applied

Scientific EffectControlled-release formulation:

Implementation Method 2

5-HTP is the immediate precursor of serotonin. 5-HTP can increase brain levels of serotonin and thereby increase the availability of serotonin for release by serotonin-enhancing compounds

Methodology Applied

Scientific EffectBiochemical conversion:

Data Source

PatentUS9901568B2Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound

Publication Date: 2018.02.27 DUKE UNIV

AI summary

This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.